Eric A. Singer, MD, MA, MS, FACS, FASCO (@eric_facs) 's Twitter Profile
Eric A. Singer, MD, MA, MS, FACS, FASCO

@eric_facs

Professor of Urology and Bioethics at The Ohio State University Comprehensive Cancer Center. Interested in Urologic Oncology, Clinical Trials, and Bioethics.

ID: 1083023255533961218

calendar_today09-01-2019 15:30:40

624 Tweet

1,1K Followers

1,1K Following

The MacLean Center (@macleanethics) 's Twitter Profile Photo

Last day to register for an illuminating talk from one of our nation's leading bioethicists! …linical-medical-ethics.ticketleap.com/43rd/

Christian Rolfo (@christianrolfo) 's Twitter Profile Photo

🚨We are hiring Medical Oncologists at Ohio State Medical Oncology ! Check the QR code below for the available positions! 3 pathways: - Physician Scientist - Clinical Scholar - Clinical Excellence Send your applications The James The Ohio State University College of Medicine

🚨We are hiring Medical Oncologists  at <a href="/OhioStateMedOnc/">Ohio State Medical Oncology</a> ! 

Check the QR code below for the available positions!  3 pathways: 
- Physician Scientist 
- Clinical Scholar
- Clinical Excellence 

Send your applications 

<a href="/OSUCCC_James/">The James</a> <a href="/OhioStateMed/">The Ohio State University College of Medicine</a>
Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

We agree with Elshad Hasanov, MD, PhD, new #kidneycancer research is the only path to achieving better understanding, care, and cures for patients 🧡 Proud to support him and researchers like YOU! Applications for KCA research grants due in ONE WEEK, submit today! kidneycancer.org/grants/

Kimryn Rathmell (@kimrynrathmell) 's Twitter Profile Photo

I’m honored to serve as the next CEO of the @osuccc_james & look forward to joining my new Buckeye colleagues at @osuwexmed & @ohiostate to take bold steps to advance the future of oncology across Ohio & nationally. Check out my LinkedIn to learn more. go.osu.edu/C4w3

Christian Rolfo (@christianrolfo) 's Twitter Profile Photo

📣Ohio State Medical Oncology The James if you’re preparing your ASCO’s agenda, include a visit at our booth in the exhibit hall! Booth 11019! You will meet our faculty members and staff. Discuss collaboration and hiring opportunities at Ohio State

📣<a href="/OhioStateMedOnc/">Ohio State Medical Oncology</a> <a href="/OSUCCC_James/">The James</a>  if you’re preparing your ASCO’s agenda, include a visit at our booth in the exhibit hall! Booth 11019!  You will meet our faculty members and staff. Discuss collaboration and hiring opportunities at <a href="/OhioState/">Ohio State</a>
Alliance for Clinical Trials in Oncology (@alliance_org) 's Twitter Profile Photo

Congratulations to Eric A. Singer, MD, MA, MS, FACS, FASCO @The James and Dr. Rebecca Snyder MD Anderson Cancer Center on their appointments as Co-Chair and Vice-Chair, respectively, of the Alliance Surgery Committee. #NCI #NCORP #NCTN #CancerResearch #AllianceSpring25

Congratulations to <a href="/eric_facs/">Eric A. Singer, MD, MA, MS, FACS, FASCO</a> @<a href="/OSUCCC_James/">The James</a> and Dr. Rebecca Snyder <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> on their appointments as Co-Chair and Vice-Chair, respectively, of the Alliance Surgery Committee. #NCI #NCORP #NCTN #CancerResearch #AllianceSpring25
KidneyCAN (@kidneycan) 's Twitter Profile Photo

Present at #KCRS25, where innovation meets collaboration! KidneyCAN is accepting abstracts now through May 19. New data is especially encouraged! 🔗 Submit yours: bit.ly/KCRS25Abstracts

Present at #KCRS25, where innovation meets collaboration!

KidneyCAN is accepting abstracts now through May 19. New data is especially encouraged!

🔗 Submit yours: bit.ly/KCRS25Abstracts
Big Ten Cancer Research Consortium (@bigtencrc) 's Twitter Profile Photo

This month’s Across the Consortium spotlights a wide range of updates from our member institutions. This issue covers everything from the effects of budget cuts to recent advances in cancer research and treatment, and more. Don’t miss it! Read more: bigtencrc.org/across-the-con…

This month’s Across the Consortium spotlights a wide range of updates from our member institutions. This issue covers everything from the effects of budget cuts to recent advances in cancer research and treatment, and more. Don’t miss it!

Read more: bigtencrc.org/across-the-con…
David Braun (@braunmdphd) 's Twitter Profile Photo

We are looking for an associate research scientist and lab manager for our translational cancer immunology lab at Yale. Please email ([email protected]) or DM me to apply. Full information about the job and the requirements can be found here: jobrxiv.org/job/yale-schoo… Pls RT!

Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

📢The KCA & UT Southwestern Medical Center invite researchers to participate in the *FIRST* RCC Animal Model Workshop this Sept 11-13! ‼️Apply by June 30, space limited‼️ Join us to drive research and accelerate therapeutics from lab to clinic. Email Salvatore La Rosa: [email protected]

📢The KCA &amp; <a href="/UTSWMedCenter/">UT Southwestern Medical Center</a> invite researchers to participate in the *FIRST* RCC Animal Model Workshop this Sept 11-13!

‼️Apply by June 30, space limited‼️

Join us to drive research and accelerate therapeutics from lab to clinic. Email <a href="/salvolarosa/">Salvatore La Rosa</a>: slarosa@kidneycancer.org
Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

🚨 NEW Request for Applications!! 🚨 We're proud to partner with #RisingTideFoundation on a new grant for "Early Detection in #KidneyCancer"! 👉Award is up to $150K per project over 2 yrs. 👉Letters of Intent due October 15. 👉 Full details kidneycancer.org/rtfccr-kca-rfp/

NEJM (@nejm) 's Twitter Profile Photo

In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity. The likelihood of a response was higher in hereditary cases than in sporadic ones. Full study results: nej.md/44aWRDP

In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity. The likelihood of a response was higher in hereditary cases than in sporadic ones. Full study results: nej.md/44aWRDP
Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

🎊 Abstract Submissions for #IKCSNA25 are Open! 🎊 Join the KCA on Nov 13-15 in Denver, CO for the 2025 IKCS: North America. Gather with top #kidneycancer experts to discuss and advance the field! But first! Submit your abstracts and register: bit.ly/44tZSiH

🎊 Abstract Submissions for #IKCSNA25 are Open! 🎊

Join the KCA on Nov 13-15 in Denver, CO for the 2025 IKCS: North America. Gather with top #kidneycancer experts to discuss and advance the field!

But first! Submit your abstracts and register: bit.ly/44tZSiH
Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

📢 Applications for TWO #KidneyCancer mentorship programs are open! Through hands-on edu & networking, we propel careers for future leaders in research and care! 🧡 KCA Mentorship Academy 🧡 Dr. Nizar Tannir #RareKidneyCancer Scholar Program Apply Now: bit.ly/45QBTMW

📢 Applications for TWO #KidneyCancer mentorship programs are open! Through hands-on edu &amp; networking, we propel careers for future leaders in research and care!

🧡 KCA Mentorship Academy

🧡 Dr. Nizar Tannir #RareKidneyCancer Scholar Program

Apply Now: bit.ly/45QBTMW